Moreover, we demonstrated that MET gene amplification and MET receptor activation are not sufficient to predict a positive effect of a combination of MET and EGFR inhibitors in erlotinib resistant NSCLC, suggesting the need of identifying other biomarkers in order to move towards a precision medicine treatment in NSCLC patients. The gene discussed is MET; the disease is non-small cell lung carcinoma.